Navigation Links
ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
Date:4/23/2009

s retains worldwide rights to ANA598, which was fully discovered at the Company. Preclinical evaluation of ANA598 was completed in the first quarter of 2008, leading to submission of an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA), subsequent allowance of the IND by the FDA and initiation of clinical investigation in the second quarter of 2008. In December 2008, Anadys announced that the FDA granted fast track designation to ANA598 for the treatment of chronic HCV.

In October 2008, Anadys initiated patient dosing in the Phase Ib study of ANA598 in HCV patients and in February 2009 Anadys initiated dosing in a 14 day study in healthy volunteers.

In an earlier Phase I study in healthy volunteers, ANA598 was administered as capsules at single oral doses of 400 mg, 800 mg, 1400 mg, 2000 mg (fed and fasted) and 3000 mg. In addition, a separate cohort received two 800 mg doses 12 hours apart. ANA598 was well tolerated at all doses and there were no serious adverse events or withdrawals from the study. All reported adverse events were classified as mild or moderate, with no apparent dose relationship. The pharmacokinetic profile demonstrated sustained plasma levels of ANA598 consistent with the potential for once-daily or twice-daily oral dosing.

In the preclinical program, ANA598 was well tolerated at all doses tested in 28-day GLP toxicology studies. In September 2008, Anadys initiated long-term, chronic toxicology studies of ANA598.

If ANA598 is successful in early stage development, the Company anticipates completion of the clinical, toxicology and manufacturing activities required to initiate Phase II studies of ANA598 in combination with current standard of care in mid-2009.

Clinical Need and Market Opportunity in HCV Infection

Chronic HCV infection is a serious public health concern affecting ap
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
2. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
3. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
6. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
7. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
8. Study Demonstrates Restylane(R) Effect Lasted 18 Months in 97% of Patients With One Repeat Injection
9. Study Demonstrates that AHCC(R) Enhances Immune System by Increasing the Production of Key Dendritic Cells
10. Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia
11. Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Tandem Diabetes Care®, Inc. (NASDAQ: TNDM ), a ... today reported its financial results for the quarter ended June ... of 2014 to the same period of 2013: , ... , t:slim Pump shipments grew 64 percent to 2,235 ... ended June 30, 2014 to the same period of 2013: ...
(Date:7/31/2014)... 31, 2014 Pharmacyclics, Inc. (the "Company") (Nasdaq: ... for the quarter ended June 30, 2014. Financial ... 2014 Revenue Total revenue for the quarter ended June ... the quarter ended June 30, 2013 primarily due to IMBRUVICA ... Total revenue for the six months ended June ...
(Date:7/31/2014)... July 31, 2014 Nektar Therapeutics (Nasdaq: ... quarter ended June 30, 2014. Cash and ... million as compared to $309.1 million at March 31, 2014."The ... Nektar as we look forward to significant milestones for a ... President and Chief Executive Officer of Nektar. "The first of ...
Breaking Medicine Technology:Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 2Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 3Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 4Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 5Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 6Pharmacyclics Reports Second Quarter 2014 Results 2Pharmacyclics Reports Second Quarter 2014 Results 3Pharmacyclics Reports Second Quarter 2014 Results 4Pharmacyclics Reports Second Quarter 2014 Results 5Pharmacyclics Reports Second Quarter 2014 Results 6Pharmacyclics Reports Second Quarter 2014 Results 7Pharmacyclics Reports Second Quarter 2014 Results 8Pharmacyclics Reports Second Quarter 2014 Results 9Pharmacyclics Reports Second Quarter 2014 Results 10Pharmacyclics Reports Second Quarter 2014 Results 11Pharmacyclics Reports Second Quarter 2014 Results 12Pharmacyclics Reports Second Quarter 2014 Results 13Pharmacyclics Reports Second Quarter 2014 Results 14Pharmacyclics Reports Second Quarter 2014 Results 15Pharmacyclics Reports Second Quarter 2014 Results 16Pharmacyclics Reports Second Quarter 2014 Results 17Pharmacyclics Reports Second Quarter 2014 Results 18Pharmacyclics Reports Second Quarter 2014 Results 19Pharmacyclics Reports Second Quarter 2014 Results 20Pharmacyclics Reports Second Quarter 2014 Results 21Pharmacyclics Reports Second Quarter 2014 Results 22Pharmacyclics Reports Second Quarter 2014 Results 23Pharmacyclics Reports Second Quarter 2014 Results 24Pharmacyclics Reports Second Quarter 2014 Results 25Pharmacyclics Reports Second Quarter 2014 Results 26Pharmacyclics Reports Second Quarter 2014 Results 27Pharmacyclics Reports Second Quarter 2014 Results 28Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 2Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 3Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 4
(Date:8/1/2014)... Cannabis use among young people has spiked, ... 17 having used marijuana at least once and 17 percent ... ‘No’ to Drugs, Say ‘Yes to Life,’ volunteers from the ... this summer with factual information about drugs, to help reverse ... “Say ‘No’ to Drugs, Say ‘Yes’ to Life,” volunteers have ...
(Date:8/1/2014)... Diego School of Medicine report that dietary capsaicin ... activation of a receptor on cells lining the intestines ... risk of colorectal tumors. , The findings are published ... Journal of Clinical Investigation . , The receptor or ... neurons, where it acts as a sentinel for heat, ...
(Date:8/1/2014)... brain plays a central role in regulating appetite and ... in the brain,s control of food intake and body ... process has been unclear. A new study ... that PPARγ activity in a type of neuron known ... response to high-fat diet. Sabrina Diano and colleagues ...
(Date:8/1/2014)... Gray HealthDay Reporter FRIDAY, Aug. ... in manufacturing jobs may have significantly less endurance than those who ... 32 people -- half were obese, half were of normal weight ... about 60 percent longer. Obesity also was associated with less ... Being older -- 50 to 65 years of age -- neither ...
(Date:8/1/2014)... (HealthDay News) -- The U.S. Food and Drug Administration ... Jardiance, to help fight type 2 diabetes. ... existing treatment regimens to control blood sugar levels in ... of the Office of Drug Evaluation II in the ... an agency statement. The FDA also recommended that ...
Breaking Medicine News(10 mins):Health News:Addressing a Serious Issue Affecting German Teens 2Health News:Pepper and halt: Spicy chemical may inhibit gut tumors 2Health News:Obesity Might Slow You Down at Work 2Health News:Obesity Might Slow You Down at Work 3Health News:FDA Approves New Type 2 Diabetes Drug 2
... WEDNESDAY, Oct. 26 (HealthDay News) -- A vaccine to prevent ... bisexual males, according to a study funded in part by ... papilloma virus (HPV), the most common sexually transmitted disease in ... and bisexual men and people infected with HIV. , ...
... the nipple is highly effective in animal models of early ... patients, according to a report by Johns Hopkins Kimmel Cancer ... 26. The results of the study are expected to lead ... early breast cancer. "Our results support the theory that ...
... human eye is as comfortable with white light generated ... popular light-emitting diodes (LEDs), according to tests conceived at ... through material to generate light, but the simpler LED ... light back and forth internally before releasing it. ...
... University Hospital surgeons found that a carefully-selected surgical care ... by nearly 50 percent. Smoking cessation at ... prior to skin closure, and using clippers over razors to ... helped reduced infection rates, according to the study published in ...
... what is so far the largest investigation of its kind, ... diseases and how they are affected by differences between two ... highly targeted, individualized therapies. Led by researchers from Weill ... edition of the journal Nature , the study provides ...
... Bisphenol A (BPA) -- a substance that may have ... thermal cash register receipts, scientists are reporting. The recycling ... BPA contamination of paper napkins, toilet paper, food packaging ... special implications for cashiers and other people who routinely ...
Cached Medicine News:Health News:HPV Vaccine Might Help Prevent Anal Cancers: Study 2Health News:Through-the-nipple breast cancer therapy shows promise in early tests 2Health News:Through-the-nipple breast cancer therapy shows promise in early tests 3Health News:High-quality white light produced by four-color laser source 2Health News:High-quality white light produced by four-color laser source 3Health News:Thomas Jefferson University Hospital cuts Whipple procedure wound infections in half with new measures 2Health News:Study identifies genetic basis of human metabolic individuality 2
Precision has its new line of programmable autoclaves which are easy to use bench-top autoclaves or models to fit any need. It has 4 adjustable sterilization programs, touch button control panel, man...
HRT II is the smallest scanning laser ever, light, portable and ready for telemedicine....
... The Horizon Phacoemulsification System ... surgical system. Lightweight and portable, ... features in a small console. ... necessary to perform anterior segment ...
Oncoseed sterile convenience pack contains fifteen Oncoseed seeds (Model 6711) loaded into a Mick disposable cartridge and steam sterilized ready to use....
Medicine Products: